

3Q 2024 EARNINGS

OCTOBER 30, 2024

BAUSCH Health

Salix
PHARMACEUTICALS

A Trusted Partner
for over 30 YEARS

Xifaxan
rifaximin 550 mg tablets



Xifaxan
rifaximin 550 mg tablets

Forward-Looking Statements; Non-GAAP Information

Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, “forward-looking statements”), including, but not limited to, statements relating to Bausch Health Companies Inc.’s (“Bausch Health” or the “Company”) future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separate its eye health business, including the timing thereof, management of its balance sheet, generation of cash, ability to launch and commercialize new products, including the timing of regulatory processes with respect to the Company’s product pipeline, ability to enforce and defend its Xifaxan® intellectual property rights, ability to execute its growth strategies generally, and other corporate and strategic transactions. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the full-year guidance, are based upon the current expectations and beliefs of management. The Company’s 2024 financial outlook and full-year guidance are included to provide further information about management’s expectations about the Company’s future business operations, activities and results and may not be appropriate for other purposes.

These forward-looking statements are subject to certain factors, risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These factors, risks and uncertainties include, but are not limited to the following: the impact of current market and economic conditions in one or more of the Company’s markets; the impact of inflation and other macroeconomic factors on the Company’s business and operations; the ability to complete the separation of Bausch + Lomb, including the timing and structure thereof, and to achieve the expected benefits thereof, and other risks and uncertainties relating to such separation, including actual and potential litigation related thereto; uncertainty of commercial success for new and existing products; challenges to patents; challenges to the Company’s ability to enforce and defend against challenges to its patents; the impact of patent expirations and the ability of the company to successfully execute strategic plans; compliance with legal and regulatory requirements; our substantial debt and current and future debt service obligations; and other factors, risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors, risks and uncertainties are incorporated herein by reference.

Additional information regarding certain of these material factors and assumptions may be found in the Company’s filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this presentation following the date of this presentation does not constitute the Company re-affirming guidance.

Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures and non-GAAP ratios to provide supplemental information to readers. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the Company’s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the Appendix hereto. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP Net income (loss), projected Adjusted Cash Flows from Operations (non-GAAP) to projected GAAP Cash Generated from Operations, projected Adjusted Gross Margin (non-GAAP) to projected GAAP Gross Margin, projected Adjusted SG&A Expense to projected GAAP SG&A Expense, projected Adjusted Tax Rate to projected GAAP tax rate and projected organic growth (non-GAAP) to projected reported revenue growth, in each case due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Many of the adjustments and exclusions used to calculate the projected non-GAAP measures may vary significantly based on actual events, so the Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to provide a GAAP calculation of these projected amounts. The amounts of these adjustments may be material and, therefore, could result in the GAAP amount being materially different from (including materially less than) the projected non-GAAP measures.

For further information on non-GAAP financial measures and ratios, please see the Non-GAAP Appendix.

Agenda



Business Update



3Q 2024 Financial Results



2024 Guidance



2024 Priorities

BUSINESS UPDATE

3Q 2024 Bausch Health (excl. B+L) Financial Highlights

- Revenue & Adjusted EBITDA¹ grew 7% and 9%, respectively
- All segments grew Revenue & Segment Profit²
- Solta Revenue & Segment Profit² up +35% and 61%, respectively
- Adjusted Operating Cash Flow¹ at \$343M, up ~75% vs. 3Q 2023
- Net Debt down \$110M
- Xifaxan[®] Revenue up \$35M; TRx³ & NRx³ up +3% and 4%, respectively, vs. 3Q 2023
- Xifaxan[®] script growth across all channels
- Raising full year guidance⁴ for Revenue, Adjusted EBITDA¹ and Adjusted Operating Cash Flow¹

6TH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE & ADJUSTED EBITDA¹ GROWTH

1. This is a non-GAAP measure of non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

3. TRx = total prescriptions, NRx = new prescriptions; Source: IQVIA.

4. See Slide 2 for further information on forward-looking statements.

2024 Strategic Priorities¹

PEOPLE

GROWTH

Expanding growth across segments and geographies

INNOVATION

Inspiring innovation and technological advancement

EFFICIENCY

Driving operational efficiency and execution

UNLOCKING VALUE

ENRICHING LIVES THROUGH OUR RELENTLESS DRIVE TO DELIVER BETTER HEALTH OUTCOMES

1. See Slide 2 for further information on forward looking statements.

3Q 2024 FINANCIAL RESULTS

BAUSCH Health

3Q 2024 GAAP Financial Results

Amounts in millions USD, except EPS amounts

	Three Months Ended		Favorable (Unfavorable)
	September 30, 2024	September 30, 2023	Reported
Revenues	\$2,510	\$2,238	12%
GAAP Gross Profit	\$1,540	\$1,358	13%
<i>GAAP Gross Margin</i>	<i>61.4%</i>	<i>60.7%</i>	<i>70 bps</i>
Selling, A&P	\$565	\$495	(14%)
GAAP G&A	\$285	\$220	(30%)
R&D	\$146	\$153	5%
GAAP Total Operating Expense	\$1,222	\$1,344	9%
GAAP Operating Income	\$318	\$14	NM¹
GAAP Net Loss Attributable to Bausch Health Companies Inc.	(\$85)	(\$378)	78%
GAAP Loss per Share Attributable to Bausch Health Companies Inc.	(\$0.23)	(\$1.03)	-
GAAP Cash Flow from Operations	\$405	\$281	44%

1. NM = Not Meaningful

3Q 2024 Non-GAAP¹ Financial Results

Amounts in millions USD


	Three Months Ended		Favorable (Unfavorable)	
	September 30, 2024	September 30, 2023	Reported	Constant Currency ¹
Revenues	\$2,510	\$2,238	12%	13%
Adj. Gross Profit¹	\$1,835	\$1,617	13%	14%
<i>Adj. Gross Margin¹</i>	<i>73.1%</i>	<i>72.3%</i>	<i>80 bps</i>	<i>-</i>
Selling, A&P (Same as reported)	\$565	\$495	(14%)	(15%)
Adj. G&A ¹	\$257	\$186	(38%)	(38%)
Adj. R&D ¹	\$146	\$152	4%	4%
Total Adj. Operating Expense¹	\$983	\$833	(18%)	(18%)
Adj. EBITA¹	\$852	\$784	9%	9%
Adj. EBITDA Attributable to Bausch Health Companies Inc.¹	\$909	\$830	10%	9%
Adj. Net Income Attributable to Bausch Health Companies Inc.¹	\$415	\$377	10%	-
<i>Diluted Shares Outstanding²</i>	<i>370.6M</i>	<i>368.5M</i>	<i>-</i>	<i>-</i>
Adj. Cash Flows from Operations^{1,3}	\$503	\$261	93%	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.


2. For the three months ended September 30, 2024 and September 30, 2023, this figure includes the dilutive impact of options and restricted stock units of approximately 2,245,000 and 3,075,000 common shares, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including this impact in this calculation would have been anti-dilutive.

3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs, and includes interest payments charged against premium.

BAUSCH+Health Consolidated REVENUE VS 3Q23



BAUSCH+Health (excl. B+L)




BAUSCH+LOMB



STRONG THIRD QUARTER PERFORMANCE ACROSS ALL SEGMENTS

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

SEGMENT MIX



■ Xifaxan ■ Relistor ■ Trulance ■ Other

REVENUE VS. 3Q23

Total – Reported: 5% Organic¹: 5%

Product	Revenue	TRx ²
Xifaxan	7%	3%
RELISTOR[®]	9%	(2%)
Trulance[®]	9%	3%

HIGHLIGHTS

- Xifaxan[®] NRx³ up 4%
- Relistor[®] & Trulance[®] Revenue up 9%
- Rest of marketed products largely flat


THIRD QUARTER REVENUE GROWTH FOR TOP 3 PRODUCTS

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. TRx = total prescriptions. Source: IQVIA.

3. NRx = new prescriptions. Source: IQVIA

SEGMENT MIX



REVENUE VS. 3Q23

Total – Reported: 6% Organic¹: 8%

Region	Reported	Organic ¹
Canada	10%	16%
EMEA	9%	3%
LATAM	(1%)	8%

HIGHLIGHTS


- Canada growth fueled by Wellbutrin®
- EMEA – Serbia up 31%² & Russia up 15%²
- LATAM – Mexico private channel up 14%²

GROWTH ACROSS CANADA, EMEA, AND LATAM


1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Organic revenue growth, which is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

GEOGRAPHIC MIX



PRODUCT MIX



HIGHLIGHTS

Total – Reported: 35% Organic¹: 36%


- China +58%², fueled by Thermage® FLX
- Korea +133%² from consumer demand
- Clear + Brilliant® Touch now in 3rd APAC market

APAC WAS A KEY DRIVER OF SOLTA GROWTH

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Organic revenue growth, which is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

SEGMENT MIX



■ Neurology ■ Dermatology ■ Generics ■ Dentistry

REVENUE VS. 3Q23

Total – Reported: 4% Organic¹: 7%

Business	Reported	Organic ¹
Neurology	25%	25%
Dermatology	0%	3%
Dentistry	(8%)	(8%)
Generics	(58%)	(52%)

HIGHLIGHTS

- Neurology – Wellbutrin® Sales up 22%
- Dermatology – CABTREO® on track
- Generics – Optimizing portfolio


NEUROLOGY WAS A KEY CONTRIBUTOR OF GROWTH

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.


Bausch + Lomb – 3Q 2024

in millions USD


BAUSCH+LOMB

Reported: **19%** Organic¹: **10%**


Vision Care

Reported: **6%** Organic¹: **6%**

Surgical

Reported: **11%** Organic¹: **10%**

Pharmaceuticals

Reported: **76%** Organic¹: **25%**

STRONG REVENUE GROWTH ACROSS ALL BUSINESSES & GEOGRAPHIES

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

3Q 2024 – Revenue & Segment Profit¹

in millions USD

Revenue	3Q 24	vs. 3Q 23
Salix	\$642	5%
International	291	6%
Diversified	269	4%
Solta	112	35%
Total	\$1,314	7%

Segment Profit ¹	3Q 24	vs. 3Q 23
Salix	\$436	2%
International	105	15%
Diversified	189	10%
Solta	53	61%
Total	\$783	8%

HIGHLIGHTS


- Lower margin due to expense timing
- Favorable product mix
- Operating leverage from net pricing
- Operating leverage on sales growth

ALL SEGMENTS GROWING REVENUE & SEGMENT PROFIT¹

1. Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

Bausch Health (excl. B+L) Debt

As of 3Q 2024, in millions USD



NET DEBT MODESTLY DECREASED – LEGAL PAYMENTS FUNDED BY OPERATIONS

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Debt values are shown at principal value. Cash balance consists of cash and cash equivalents and restricted cash. Net debt is net of cash and cash equivalents and restricted cash. Amounts shown may not foot due to rounding.

2024 GUIDANCE

Updating Full Year 2024 Guidance^{1,2}

All amounts are approximate and in USD

	2024 Guidance ^{1,2}					
	Prior BHC	Current BHC	Prior B+L	Current B+L	Prior BHC excl. B+L	Current BHC excl. B+L
Net Revenue	\$9.40B - \$9.65B	\$9.500B - \$9.675B	\$4.70B - \$4.80B	\$4.725B - \$4.825B	\$4.70B - \$4.85B	\$4.775B - \$4.850B
Organic Growth¹					2% - 5%	4% - 6%
Adjusted EBITDA (non-GAAP)^{1,4}	\$3.21B - \$3.36B	\$3.275B - \$3.375B	\$850M - \$900M	\$850M - \$900M	\$2.36B - \$2.46B	\$2.425B - \$2.475B
Adjusted Operating Cash Flow (non-GAAP)^{1,3}					\$775M - \$825M	\$975M - \$1,025M
Adjusted Gross Margin¹					~80%	~81%
R&D Expense					~\$325M	~\$300M
Interest Expense⁵					~\$1.3B	~\$1.3B
Adjusted Tax Rate (non-GAAP)¹					15%-18%	15%-18%
Capital Expenditures					~\$60M	~\$55M

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. See Slide 2 for further information on forward-looking statements.

3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs and interest payments charged against premium.

4. Bausch Health (excl. B+L) Adjusted EBITDA above includes approximately \$8 million in 2024 of net benefit from Transition Service Agreements with Bausch + Lomb in connection with the Separation of Bausch + Lomb, as income for services provided to Bausch + Lomb exceeds charges for services provided by Bausch + Lomb. These amounts eliminate in consolidation.

5. On September 30, 2022, the Company closed a series of transactions (the "Exchange") whereby it exchanged validly tendered senior unsecured notes for newly issued secured notes (the "New Secured Notes"). The accounting for the Exchange resulted in the calculation of interest expense under GAAP using effective interest rates on the New Secured Notes which are significantly lower than the stated interest rates of the New Secured Notes. As a result, interest guidance has been presented based on interest as calculated using contractual principal and interest, including amortization and write-down of deferred financing costs of approximately \$35M.

**Increase
Bausch
Health
Enterprise
Value**

**Maximize the
Value of our
BLCO Asset**

**Optimize our
Capital
Structure**

WORKING ALL LEVERS OF VALUE CREATION

1. See Slide 2 for further information on forward-looking statements.

2024 PRIORITIES



2024 Strategic Priorities¹

PEOPLE

Drive results-oriented culture of accountability

GROWTH

Deliver on Revenue, Adjusted EBITDA² and Adjusted Operating Cash Flow² Commitments

INNOVATION

Intensify focus and operating rigor behind R&D and business development

EFFICIENCY

Execute with operational excellence and a cost-focused mindset across the enterprise

UNLOCKING VALUE

Continue to evaluate strategic alternatives; achieving full separation of B+L remains a priority

ENRICHING LIVES THROUGH OUR RELENTLESS DRIVE TO DELIVER BETTER HEALTH OUTCOMES

1. See Slide 2 for further information on forward looking statements.

2. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Key Takeaways

**Sixth
Consecutive
Quarter of
Growth**

**Raising
FY 2024
Guidance¹**

**Delivering
On Our
Commitments**

**Working All
Levers Of
Value
Creation**

OUR EXECUTION PROVIDES STRONG FOUNDATION FOR CONTINUED MOMENTUM ACROSS OUR BUSINESS

1. See Slide 2 for further information on forward-looking statements.

The background is an abstract composition of various geometric shapes, primarily triangles and polygons, in shades of blue and orange. The shapes are layered and overlap, creating a sense of depth and movement. The colors transition from a deep blue on the left to a bright orange on the right.

BAUSCH  Health

APPENDIX

On Track With Our Key R&D Initiatives¹

Key Clinical Programs	Phase 1	Phase 2	Phase 3	Approval/Launch	Notes
DERMATOLOGY					
CABTREO® First triple combination product for the treatment of acne vulgaris					Successful U.S. commercial launch in 1Q 2024 Received approval in Canada in 3Q 2024 Launched in Canada in October 2024
SALIX					
RED-C Prevention and delay of first episode of hepatic encephalopathy					Both RED-C global Phase 3 trials currently in treatment phase On track for top-line Phase 3 results by early 2026
Amiselimod (S1P modulator): Treatment for mild to moderate ulcerative colitis					Submitted draft protocols for Phase 3 trial addressing moderate- to severe- Ulcerative Colitis patients; Agreement on study protocols from FDA, EMA (EU), and PMDA (Japan) expected by year-end 2024 Evaluating potential Phase 2 study for Crohn's disease
SOLTA MEDICAL					
Thermage® FLX Radio-frequency technology to help tighten and improve the smoothness and texture of skin's surface					Received National Medical Products Administration (NMPA) approval in China in January 2024, followed by a successful launch Plan to submit for approval in Canada during 4Q 2024
Clear + Brilliant® Touch Fractionated laser device for skin rejuvenation					Awaiting European regulatory response to submission with additional Asia Pacific markets and Canada thereafter Launched in the Philippines in 3Q 2024, adding to approved launches ex-U.S. this year in Australia, New Zealand
Next Generation Fraxel® Fractionated laser device for skin resurfacing					Received FDA clearance in August 2024 U.S. commercial launch expected in 2025

1. Progress timelines are for illustrative purposes only; See Slide 2 for further information on forward-looking statements.

Balance Sheet Summary

In millions USD


	As of 9.30.2024	As of 12.31.2023	As of 12.31.2022
Cash and cash equivalents ¹	\$750	\$962	\$591
Revolving Credit Facilities	\$350 ⁵	\$275 ⁵	\$470
AR Credit Facility	\$300	\$350	\$-
Senior Secured Debt (principal amount) ²	\$15,112	\$15,203	\$13,300
Senior Unsecured Debt (principal amount) ²	\$5,247	\$5,803	\$5,810
Total Consolidated Debt (principal amount)²	\$20,359	\$21,006	\$19,110
Total Consolidated Debt (net of premiums and discounts)	\$21,507	\$22,388	\$20,766
Net Consolidated Debt (principal amount)³	\$19,640	\$20,059	\$18,546
TTM GAAP Net Loss	(\$217)	(\$611)	(\$212)
TTM Adj. EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)⁴	\$3,241	\$3,014	\$3,022

WE CONTINUE TO PRIORITIZE LIQUIDITY MANAGEMENT AND THE DE-LEVERING OF OUR BALANCE SHEET

1. Cash and cash equivalents includes restricted cash of \$31M, \$15M and \$27M as of 9/30/24, 12/31/23 and 12/31/22, respectively.
2. Debt balances shown at principal value. Senior secured debt figure is inclusive of revolving credit facilities drawn (if any), AR Credit Facility and \$1,900M of secured debt for Bausch + Lomb's acquisition of Xiidra in 3Q 2023.
3. Net consolidated debt is net of unrestricted cash and cash equivalents.
4. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
5. No outstanding borrowings under Bausch Health (excl. B+L) revolving credit facility at September 30, 2024 and December 31, 2023.

Bausch Health (excl. B+L) Debt Maturity Profile¹

As of 3Q 2024, in millions USD



Bausch Health
(excl. B+L) Debt
Total:
\$15.7B¹
Restricted: \$14.4B
Unrestricted: \$1.3B²

Reduced debt by:
~\$30M
in 3Q 2024

Reduced debt,
net of cash, by:
~\$110M
in 3Q 2024

WE CONTINUE TO EVALUATE ALTERNATIVES TO REDUCE OUR OVERALL LEVERAGE WHILE ALSO FOCUSING ON OUR MATURITY PROFILE

1. Debt values are shown at principal value. Does not include ~\$3B of Bausch + Lomb term loans, \$350M of Bausch + Lomb revolving credit facility, and ~\$1.4B of Bausch + Lomb senior secured notes.

2. Consists of \$1B non-recourse debt issued by a wholly-owned unrestricted subsidiary, 1375209 B.C. Ltd., that owns ~38.5% of the issued and outstanding shares of Bausch + Lomb, and \$300M outstanding under AR credit facility.

3Q & YTD24 Revenue Performance

Amounts in millions USD

	3Q24	3Q23	Reported	Organic ¹	YTD24	YTD23	Reported	Organic ¹
Salix	\$642	\$614	5%	5%	\$1,699	\$1,667	2%	3%
International	\$291	\$275	6%	8%	\$832	\$781	7%	5%
Solta Medical	\$112	\$83	35%	36%	\$302	\$244	24%	26%
Neurology	\$170	\$136	25%	25%	\$401	\$353	14%	14%
Dermatology	\$61	\$61	-	3%	\$185	\$165	12%	17%
Generics	\$16	\$38	(58%)	(52%)	\$65	\$92	(29%)	(21%)
Dentistry	\$22	\$24	(8%)	(8%)	\$71	\$74	(4%)	(4%)
Diversified	\$269	\$259	4%	7%	\$722	\$684	6%	8%
Bausch Health (excl. B+L)	\$1,314	\$1,231	7%	8%	\$3,555	\$3,376	5%	6%
Vision Care	\$684	\$648	6%	6%	\$2,016	\$1,881	7%	8%
Surgical	\$206	\$185	11%	10%	\$612	\$563	9%	9%
Pharmaceuticals	\$306	\$174	76%	25%	\$883	\$529	67%	20%
Bausch + Lomb	\$1,196	\$1,007	19%	10%	\$3,511	\$2,973	18%	10%
Total Bausch Health	\$2,510	\$2,238	12%	9%	\$7,066	\$6,349	11%	8%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

YTD GAAP Financial Results

Amounts in millions USD, except EPS amounts

	Nine Months Ended		Favorable (Unfavorable)
	September 30, 2024	September 30, 2023	Reported
Revenues	\$7,066	\$6,349	11%
GAAP Gross Profit	\$4,187	\$3,646	15%
<i>GAAP Gross Margin</i>	<i>59.3%</i>	<i>57.4%</i>	<i>190 bps</i>
Selling, A&P	\$1,717	\$1,468	(17%)
GAAP G&A	\$759	\$683	(11%)
R&D	\$453	\$452	-
GAAP Total Operating Expense	\$3,199	\$3,045	(5%)
GAAP Operating Income	\$988	\$601	64%
GAAP Net Loss Attributable to Bausch Health Companies Inc.	(\$139)	(\$553)	75%
GAAP Loss per Share Attributable to Bausch Health Companies Inc.	(\$0.38)	(\$1.52)	-
GAAP Cash Flow from Operations	\$996	\$642	55%

YTD Non-GAAP¹ Financial Results

Amounts in millions USD

	Nine Months Ended		Favorable (Unfavorable)	
	September 30, 2024	September 30, 2023	Reported	Constant Currency ¹
Revenues	\$7,066	\$6,349	11%	12%
Adj. Gross Profit¹	\$5,072	\$4,497	13%	13%
<i>Adj. Gross Margin¹</i>	<i>71.8%</i>	<i>70.8%</i>	<i>100 bps</i>	<i>-</i>
Selling, A&P (Same as reported)	\$1,717	\$1,468	(17%)	(18%)
Adj. G&A ¹	\$667	\$580	(15%)	(15%)
Adj. R&D ¹	\$452	\$451	-	-
Total Adj. Operating Expense¹	\$2,854	\$2,499	(14%)	(15%)
Adj. EBITA¹	\$2,218	\$1,998	11%	12%
Adj. EBITDA Attributable to Bausch Health Companies Inc.¹	\$2,372	\$2,145	11%	10%
Adj. Net Income Attributable to Bausch Health Companies Inc.¹	\$964	\$868	11%	-
<i>Diluted Shares Outstanding²</i>	370.4M	367.4M	-	-
Adj. Cash Flows from Operations^{1,3}	\$971	\$458	112%	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. For the nine months ended September 30, 2024 and 2023 this figure includes the dilutive impact of options and restricted stock units of approximately 2,656,000 and 2,931,000 common shares, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in this calculation would have been anti-dilutive.

3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs, and includes interest payments charged against premium.

Inventory in Select U.S. Businesses (QTD)¹

Business Units	As of Jun 30, 2023	As of Sep 30, 2023	Change 3Q23	As of Jun 30, 2024	As of Sep 30, 2024	Change 3Q24
Dermatology	1.03	1.17	0.14	1.16	1.14	(0.02)
Neurology	1.12	1.18	0.06	1.08	1.12	0.04
Salix	1.10	1.25	0.15	1.18	1.10	(0.08)

1. U.S. wholesale inventory

Inventory in Select U.S. Businesses (YTD)¹

Business Units	As of Dec 31, 2022	As of Sep 30, 2023	Change YTD23	As of Dec 31, 2023	As of Sep 30, 2024	Change YTD24
Dermatology	1.07	1.17	0.10	1.04	1.14	0.10
Neurology	1.17	1.18	0.01	1.18	1.12	(0.06)
Salix	1.02	1.25	0.23	1.20	1.10	(0.10)

1. U.S. wholesale inventory

Other Financial Information

In millions USD

	Three Months Ended		Favorable (Unfavorable)		Nine Months Ended		Favorable (Unfavorable)	
	September 30, 2024	September 30, 2023	Reported	Constant Currency ¹	September 30, 2024	September 30, 2023	Reported	Constant Currency ¹
Cash Interest Paid ²	\$451	\$337	(34%)	(34%)	\$1,301	\$1,083	(20%)	(20%)
Net Interest Expense (GAAP)	\$339	\$333	(2%)	(2%)	\$1,027	\$946	(9%)	(8%)
Non-cash adjustments								
Depreciation	\$48	\$48	-	2%	\$142	\$140	(1%)	(1%)
Non-cash share-based Comp	\$38	\$29	(31%)	(31%)	\$107	\$103	(4%)	(4%)
Additional cash items								
Contingent Consideration	\$10	\$8	-	-	\$27	\$22	-	-
Milestones/License Agreements and Other Intangibles	\$18	\$3	-	-	\$20	\$11	-	-
Restructuring and Other	\$19	\$14	-	-	\$65	\$33	-	-
Capital Expenditures	\$71	\$42	-	-	\$231	\$117	-	-
Adj. Tax Rate ¹	17.2%	16.0%	-	-	16.4%	14.0%	-	-
GAAP Tax Rate	44.1%	14.6%	-	-	89.8%	45.4%	-	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Cash interest paid includes payments recorded against debt premiums.

Non-GAAP Adjustments EPS Impact

In millions USD

	Three Months Ended				Nine Months Ended			
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023	
	Income (Expense)	EPS Impact ²	Income (Expense)	EPS Impact ²	Income (Expense)	EPS Impact ²	Income (Expense)	EPS Impact ²
Net loss	(\$92)	(\$0.25)	(\$382)	(\$1.05)	(\$170)	(\$0.46)	(\$564)	(\$1.55)
Non-GAAP adjustments:¹								
Amortization of intangible assets	274	0.74	253	0.69	818	2.21	795	2.16
Goodwill impairments	-	-	402	1.09	-	-	402	1.09
Asset impairments	-	-	4	0.01	6	0.02	54	0.15
Restructuring, integration and transformation costs	9	0.02	31	0.08	54	0.15	85	0.23
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	48	0.13	60	0.16	83	0.22	77	0.21
Gain on extinguishment of debt	-	-	-	-	(23)	(0.06)	-	-
IT infrastructure investment	7	0.02	8	0.02	27	0.07	22	0.06
Separation costs and separation-related costs	2	0.01	6	0.02	12	0.03	20	0.05
Legal and other professional fees	11	0.03	4	0.01	25	0.07	17	0.05
(Gain) loss on sale of assets, net	(5)	(0.01)	(5)	(0.01)	(10)	(0.03)	(4)	(0.01)
Litigation and other matters, net of insurance recoveries	188	0.51	24	0.07	215	0.58	(55)	(0.15)
Other	1	-	2	0.01	12	0.03	9	0.02
Tax effect of non-GAAP ¹ adjustments	(18)	(0.05)	(17)	(0.05)	(66)	(0.18)	36	0.10
EPS difference between basic and diluted shares	-	-	-	0.01	-	-	-	0.02
Adjusted net income (non-GAAP)¹	425	-	390	-	983	-	894	-
Adjusted net income attributable to noncontrolling interest (non-GAAP) ¹	(10)	(0.03)	(13)	(0.04)	(19)	(0.05)	(26)	(0.07)
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)¹	\$415	-	\$377	-	\$964	-	\$868	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Includes 2,245,000 and 3,075,000 diluted shares for the three months ended September 30, 2024 and 2023, respectively, and 2,656,000 and 2,931,000 diluted shares for the nine months ended September 30, 2024 and 2023, respectively, as the inclusion of these shares would be anti dilutive.

3Q24 Reconciliation of Reported Operating Income to Adjusted EBITA (Non-GAAP)¹

In millions USD

	3Q24							3Q23						
	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income
GAAP Operating Income	\$1,540	61.4%	\$565	\$285	\$146	\$1,222	\$318	\$1,358	60.7%	\$495	\$220	\$153	\$1,344	\$14
Amortization of intangible assets	274	10.9%	-	-	-	-	274	253	11.3%	-	-	-	-	253
Goodwill impairments	-	-	-	-	-	-	-	-	-	-	-	-	(402)	402
Asset impairments	-	-	-	-	-	-	-	4	0.2%	-	-	-	-	4
Restructuring, integration and transformation costs	-	-	-	(9)	-	(9)	9	-	-	-	(19)	-	(30)	30
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	21	0.8%	-	-	-	(27)	48	2	0.1%	-	-	-	(44)	44
IT infrastructure investment	-	-	-	(7)	-	(7)	7	-	-	-	(8)	-	(8)	8
Separation costs and separation-related costs	-	-	-	(1)	-	(2)	2	-	-	-	(3)	(1)	(4)	6
Legal and other professional fees	-	-	-	(11)	-	(11)	11	-	-	-	(4)	-	(4)	4
(Gain) loss on sale of assets, net	-	-	-	-	-	5	(5)	-	-	-	-	-	5	(5)
Litigation and other matters	-	-	-	-	-	(188)	188	-	-	-	-	-	(24)	24
Adjusted EBITA (Non-GAAP)¹	\$1,835	73.1%	\$565	\$257	\$146	\$983	\$852	\$1,617	72.3%	\$495	\$186	\$152	\$833	\$784

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

YTD24 Reconciliation of Reported Operating Income to Adjusted EBITA (Non-GAAP)¹

In millions USD

	YTD24							YTD23						
	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income
GAAP Operating Income	\$4,187	59.3%	\$1,717	\$759	\$453	\$3,199	\$988	\$3,646	57.4%	\$1,468	\$683	\$452	\$3,045	\$601
Amortization of intangible assets	818	11.6%	-	-	-	-	818	795	12.5%	-	-	-	-	795
Goodwill impairments	-	-	-	-	-	-	-	-	-	-	-	-	(402)	402
Asset impairments	6	0.1%	-	-	-	-	6	54	0.9%	-	-	-	-	54
Restructuring, integration and transformation costs	-	-	-	(31)	-	(54)	54	-	-	-	(48)	-	(85)	85
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	61	0.9%	-	-	-	(22)	83	2	-	-	-	-	(59)	61
IT infrastructure investment	-	-	-	(27)	-	(27)	27	-	-	-	(22)	-	(22)	22
Separation costs and separation-related costs	-	-	-	(9)	(1)	(12)	12	-	-	-	(16)	(1)	(20)	20
Legal and other professional fees	-	-	-	(25)	-	(25)	25	-	-	-	(17)	-	(17)	17
(Gain) loss on sale of assets, net	-	-	-	-	-	10	(10)	-	-	-	-	-	4	(4)
Litigation and other matters	-	-	-	-	-	(215)	215	-	-	-	-	-	55	(55)
Adjusted EBITA (Non-GAAP)¹	\$5,072	71.8%	\$1,717	\$667	\$452	\$2,854	\$2,218	\$4,497	70.8%	\$1,468	\$580	\$451	\$2,499	\$1,998

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Reconciliation of Reported Net Loss to EBITDA¹ and Adjusted EBITDA¹

In millions USD

	Three months ended September 30,		Nine months ended September 30,	
	2024	2023	2024	2023
Net loss	(\$92)	(\$382)	(\$170)	(\$564)
Interest expense, net	339	333	1,027	946
Provision for income taxes	71	56	128	181
Depreciation and amortization	322	301	960	935
EBITDA	640	308	1,945	1,498
Adjustments:				
Goodwill impairments	-	402	-	402
Asset impairments	-	4	6	54
Restructuring, integration, and transformation costs	9	31	54	85
Acquisition related costs and adjustments (excluding amortization of intangible assets)	48	45	83	62
Gain on extinguishment of debt	-	-	(23)	-
Share-based compensation	38	29	107	103
Separation costs and separation-related costs	2	6	12	20
Other adjustments:				
Litigation and other matters, net of insurance recoveries	188	24	215	(55)
IT infrastructure investment	7	8	27	22
Legal and other professional fees	11	4	25	17
(Gain) loss on sale of assets, net	(5)	(5)	(10)	(4)
Other	1	2	12	9
Adjusted EBITDA (non-GAAP)¹	939	858	2,453	2,213
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	(30)	(28)	(81)	(68)
Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)¹	\$909	\$830	\$2,372	\$2,145

	Three months ended September 30,		Nine months ended September 30,	
	2024	2023	2024	2023
Net income attributable to noncontrolling interest	\$7	\$4	\$31	\$11
Noncontrolling interest portion of adjustments for:				
Interest expense, net	(12)	(9)	(35)	(21)
Depreciation and amortization	(13)	(9)	(38)	(29)
All other adjustments	(12)	(14)	(39)	(29)
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP)¹	(\$30)	(\$28)	(\$81)	(\$68)

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

3Q24 Segment Profit² Reconciliation to Adjusted EBITDA¹

In millions USD

	Three Months Ended September 30, 2024			Three Months Ended September 30, 2023		
	Revenue	Segment Profit ²	Segment Profit Margin	Revenue	Segment Profit ²	Segment Profit Margin
Salix	\$642	\$436	68%	\$614	\$429	70%
International	291	105	36%	275	91	33%
Solta Medical	112	53	47%	83	33	40%
Diversified Products	269	189	70%	259	172	66%
Total Bausch Health (excluding B+L)	\$1,314	\$783	60%	\$1,231	\$725	59%
Bausch + Lomb	1,196	283	24%	1,007	244	24%
Total	\$2,510	\$1,066	42%	\$2,238	\$969	43%
Corporate		(248)			(222)	
Adjustments:						
Fair value inventory step-up resulting from acquisitions	-	21	-	-	2	-
IT infrastructure investment	-	7	-	-	8	-
Legal and other professional fees	-	11	-	-	4	-
Separation-related costs	-	1	-	-	4	-
Transformation Costs	-	9	-	-	19	-
Acquired in-process research and development costs	-	(15)	-	-	-	-
Adjusted EBITA (non-GAAP) ¹	-	\$852	-	-	\$784	-
Depreciation	-	48	-	-	48	-
Share-based compensation	-	38	-	-	29	-
Foreign exchange and other	-	1	-	-	(3)	-
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	-	(30)	-	-	(28)	-
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) ¹	-	\$909	-	-	\$830	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

YTD24 Segment Profit² Reconciliation to Adjusted EBITDA¹ BAUSCH+Health

In millions USD

	Nine Months Ended September 30, 2024			Nine Months Ended September 30, 2023		
	Revenue	Segment Profit ²	Segment Profit Margin	Revenue	Segment Profit ²	Segment Profit Margin
Salix	\$1,699	\$1,142	67%	\$1,667	\$1,129	68%
International	832	278	33%	781	236	30%
Solta Medical	302	140	46%	244	114	47%
Diversified Products	722	469	65%	684	417	61%
Total Bausch Health (excluding B+L)	\$3,555	\$2,029	57%	\$3,376	\$1,896	56%
Bausch + Lomb	3,511	799	23%	2,973	699	24%
Total	\$7,066	\$2,828	40%	\$6,349	\$2,595	41%
Corporate		(746)			(703)	
Adjustments:						
Fair value inventory step-up resulting from acquisitions	-	61	-	-	2	-
IT infrastructure investment	-	27	-	-	22	-
Legal and other professional fees	-	25	-	-	17	-
Separation-related costs	-	10	-	-	17	-
Transformation Costs	-	31	-	-	48	-
Acquired in-process research and development costs	-	(18)	-	-	-	-
Adjusted EBITA (non-GAAP) ¹	-	\$2,218	-	-	\$1,998	-
Depreciation	-	142	-	-	140	-
Share-based compensation	-	107	-	-	103	-
Foreign exchange and other	-	(14)	-	-	(28)	-
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	-	(81)	-	-	(68)	-
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) ¹	-	\$2,372	-	-	\$2,145	-

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

	For Three Months Ended							Change in Reported Revenue		Change in Organic Revenue ¹	
	September 30, 2024				September 30, 2023						
	Revenue as reported	Changes in Exchange Rates ²	Acquisitions	Organic Revenue (Non-GAAP) ¹	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ¹	Amount	Pct.	Amount	Pct.
Salix	\$642	\$-	\$-	\$642	\$614	(\$4)	\$610	\$28	5%	\$32	5%
International	291	3	-	294	275	(2)	273	16	6%	21	8%
Solta Medical	112	1	-	113	83	-	83	29	35%	30	36%
Neurology	170	-	-	170	136	-	136	34	25%	34	25%
Dermatology	61	-	-	61	61	(2)	59	-	-	2	3%
Generics	16	-	-	16	38	(5)	33	(22)	(58%)	(17)	(52%)
Dentistry	22	-	-	22	24	-	24	(2)	(8%)	(2)	(8%)
Diversified	269	-	-	269	259	(7)	252	10	4%	17	7%
Bausch Health (excl. B+L)	\$1,314	\$4	\$-	\$1,318	\$1,231	(\$13)	\$1,218	\$83	7%	\$100	8%
Vision Care	684	4	-	688	648	-	648	36	6%	40	6%
Surgical	206	1	(4)	203	185	-	185	21	11%	18	10%
Pharmaceuticals	306	-	(92)	214	174	(3)	171	132	76%	43	25%
Total Bausch + Lomb	\$1,196	\$5	(\$96)	\$1,105	\$1,007	(\$3)	\$1,004	\$189	19%	\$101	10%
Total Bausch Health	\$2,510	\$9	(\$96)	\$2,423	\$2,238	(\$16)	\$2,222	\$272	12%	\$201	9%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

In millions USD

	For Nine Months Ended							Change in Reported Revenue		Change in Organic Revenue ¹	
	September 30, 2024				September 30, 2023						
	Revenue as reported	Changes in Exchange Rates ²	Acquisitions	Organic Revenue (Non-GAAP) ¹	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ¹	Amount	Pct.	Amount	Pct.
Salix	\$1,699	\$-	\$-	\$1,699	\$1,667	(\$18)	\$1,649	\$32	2%	\$50	3%
International	832	(16)	-	816	781	(6)	775	51	7%	41	5%
Solta Medical	302	6	-	308	244	-	244	58	24%	64	26%
Neurology	401	-	-	401	353	-	353	48	14%	48	14%
Dermatology	185	-	-	185	165	(7)	158	20	12%	27	17%
Generics	65	-	-	65	92	(10)	82	(27)	(29%)	(17)	(21%)
Dentistry	71	-	-	71	74	-	74	(3)	(4%)	(3)	(4%)
Diversified	722	-	-	722	684	(17)	667	38	6%	55	8%
Bausch Health (excl. B+L)	\$3,555	(\$10)	\$-	\$3,545	\$3,376	(\$41)	\$3,335	\$179	5%	\$210	6%
Vision Care	2,016	42	(24)	2,034	1,881	(1)	1,880	135	7%	154	8%
Surgical	612	6	(4)	614	563	-	563	49	9%	51	9%
Pharmaceuticals	883	4	(260)	627	529	(6)	523	354	67%	104	20%
Total Bausch + Lomb	\$3,511	\$52	(\$288)	\$3,275	\$2,973	(\$7)	\$2,966	\$538	18%	\$309	10%
Total Bausch Health	\$7,066	\$42	(\$288)	\$6,820	\$6,349	(\$48)	\$6,301	\$717	11%	\$519	8%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

3Q24 & YTD24 Reconciliation of Reported Cash Provided by Operating Activities to Adjusted Cash Flows from Operations (Non-GAAP)¹

In millions USD

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Cash provided by operating activities	\$405	\$281	\$996	\$642
Payments of legacy legal settlements, net of insurance proceeds	216	-	216	(79)
Payments of transformation costs	5	15	22	51
Payments of separation costs and separation-related costs	3	5	10	16
Interest payments charged against premium	(126)	(40)	(273)	(174)
Third party fees paid in connection with the Exchange	-	-	-	2
Adjusted cash flows from operations (non-GAAP) ¹	\$503	\$261	\$971	\$458

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Consolidated
3Q24 & YTD24 Reconciliation of Reported Cash Provided by Operating Activities to
Adjusted Cash Flows from Operations (non-GAAP)¹
In millions USD

	Three Months Ended September 30, 2024			Nine Months Ended September 30, 2024		
	Bausch Health Companies Inc.	B+L	Bausch Health (excl. B+L) ²	Bausch Health Companies Inc.	B+L	Bausch Health (excl. B+L) ²
Cash provided by operating activities	\$405	\$154	\$251	\$996	\$210	\$787
Payments of legacy legal settlements, net of insurance proceeds	216	-	216	216	-	216
Payments of transformation costs	5	5	-	22	18	4
Payments of separation costs and separation-related costs	3	-	2	10	3	7
Interest payments charged against premium	(126)	-	(126)	(273)	-	(273)
Adjusted cash flows from operations (non-GAAP) ¹	\$503	\$159	\$343	\$971	\$231	\$741

1. This is a non-GAAP measure. Management considers the presentation of Adjusted cash flows from operations for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted cash flows from operations for Bausch Health (excl. B+L) (non-GAAP) is not intended to be representative of GAAP operating activities and Adjusted cash flows from operating activities for B+L is not intended to be representative of discontinued operations as the criteria for that accounting hasn't been met. As such, Adjusted cash flows from operations excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted cash flows from operations attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

2. Amounts may not cross foot due to rounding.

Trailing Twelve Months Adjusted EBITDA¹

In millions USD

	Trailing Twelve Months Ended				
	Sep-24	Jun-24	Mar-24	Dec-23	Sep-23
Net Loss	(\$217)	(\$507)	(\$479)	(\$611)	(\$974)
Interest expense, net	1,383	1,377	1,347	1,302	1,247
Provision for income taxes	168	153	156	221	234
Depreciation and amortization	1,289	1,268	1,265	1,264	1,295
EBITDA	2,623	2,291	2,289	2,176	1,802
Adjustments:					
Goodwill impairments	91	493	493	493	1,024
Asset impairments	6	10	42	54	54
Restructuring, integration and transformation costs	85	107	108	116	105
Acquisition related costs and adjustments (excluding amortization of intangible assets)	127	124	93	106	90
Gain on extinguishment of debt	(24)	(24)	(12)	(1)	(192)
Share-based compensation	136	127	124	132	138
Separation costs and separation-related costs	18	22	25	26	33
Other adjustments:					
Litigation and other matters, net of insurance recoveries	217	53	(39)	(53)	(53)
IT infrastructure investment	36	37	34	31	27
Legal and other professional fees	28	21	23	20	22
Gain on sale of assets, net	(9)	(9)	(7)	(3)	(6)
Other	16	17	20	13	10
Adjusted EBITDA (non-GAAP)¹	3,350	3,269	3,193	3,110	3,054
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	(109)	(107)	(102)	(96)	(86)
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP)¹	\$3,241	\$3,162	\$3,091	\$3,014	\$2,968

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Reconciliation of Reported Net (Loss) Income to Adjusted EBITDA¹

In millions USD

	Three Months Ended September 30, 2024			Three Months Ended September 30, 2023		
	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³
Net (Loss) Income	(\$92)	\$8	(\$100)	(\$382)	(\$76)	(\$309)
Interest expense, net	339	96	243	333	72	260
Provision for income taxes	71	(66)	137	56	45	11
Depreciation and amortization	322	110	212	301	82	219
EBITDA	640	148	492	308	123	181
Adjustments:						
Goodwill impairments	-	-	-	402	-	402
Asset impairments	-	-	-	4	-	4
Restructuring, integration and transformation costs	9	11	(2)	31	15	16
Acquisition related costs and adjustments (excluding amortization of intangible assets)	48	24	24	45	13	32
Gain on extinguishment of debt	-	-	-	-	-	-
Share-based compensation	38	24	14	29	16	13
Separation costs and separation-related costs	2	(1)	3	6	2	5
Other adjustments:						
Litigation and other matters	188	1	187	24	2	21
IT infrastructure investment	7	7	-	8	19	(10)
Legal and other professional fees	11	2	9	4	(1)	5
Net (gain) loss on sale of assets	(5)	-	(5)	(5)	-	(5)
Other	1	-	1	2	2	-
Adjusted EBITDA (non-GAAP)^{1,2}	939²	216²	723	858²	191²	664

1. This is a non-GAAP measure. Management considers the presentation of Adjusted EBITDA for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be representative of GAAP continuing operations and Adjusted EBITDA for B+L is not intended to be representative of discontinued operations as the criteria for that accounting hasn't been met. As such, Adjusted EBITDA excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented. See Slide 2 and Non-GAAP Appendix for further information on this and other non-GAAP measures and ratios.
2. Adjusted EBITDA (non-GAAP) above includes Adjusted EBITDA attributable to noncontrolling interests. For Bausch Health Companies Inc., this amounted to \$30 million and \$28 million for the three months ended September 30, 2024 and 2023, which includes \$4 million and \$4 million, respectively related to B+L.
3. Amounts may not cross foot due to rounding.

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses certain non-GAAP financial measures and non-GAAP ratios. These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Adjusted EBITDA and Adjusted EBITDA Attributable to Bausch Health

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and certain other items described below. Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) as defined below.

Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflect our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and the following items:

- **Restructuring, integration and transformation costs:** The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the B+L IPO, as the Company prepares for post-separation operations, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company's restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party

advisory costs, as well as certain severance-related costs (including the severance costs associated with the departure of Bausch + Lomb's former CEO). Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

- **Asset Impairments:** The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments of intangible assets and assets held for sale from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
- **Goodwill Impairments:** The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.
- **Share-based compensation:** The Company has excluded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
- **Acquisition-related costs and adjustments excluding amortization of intangible assets:** The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the company excludes acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.
- **Gain (Loss) on extinguishment of debt:** The Company has excluded gain (loss) on extinguishment of debt as this represents a gain or loss from refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control.

- **Separation costs and separation-related costs:** The Company has excluded certain costs incurred in connection with activities regarding the separation of the eye-health business. Separation costs are incremental costs directly related to effectuating the separation of the eye-health business and include, but are not limited to, legal, audit and advisory fees. Separation-related costs are incremental costs indirectly related to the separation of the eye-health business and include, but are not limited to rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
- **Other adjustments:** The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets or other disposition of assets. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company has also excluded IT infrastructure investments that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. The Company has also excluded certain other costs, including professional fees associated with contemplated, but not completed, strategic transactions. The Company excluded these costs as the consideration of such matters are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Adjusted Net Income and Adjusted Net Income attributable to Bausch Health

Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP financial measure), adjusted for asset impairments, goodwill impairments, restructuring, integration and transformation costs, acquisition-

related costs and adjustments excluding amortization of intangible assets, gain (loss) on extinguishment of debt, separation costs and separation-related costs and other non-GAAP adjustments as these adjustments are described above, and amortization of intangible assets and acquisition-related costs and adjustments excluding amortization of intangible assets, as described below:

- **Amortization of intangible assets:** The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.
- **Acquisition-related costs and adjustments excluding amortization of intangible assets:** In addition to the acquisition-related costs and adjustments as described above, the company has excluded the expense directly attributable to one-time commitment and structuring fees related to a bridge loan facility put in place prior to the acquisition of Xiidra and certain other ophthalmology assets. The company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors.

Adjusted net income attributable to Bausch Health (non-GAAP) is Adjusted net income (non-GAAP) further adjusted to exclude the Adjusted net income attributable to noncontrolling interest (non-GAAP). Adjusted net income attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Historically, management has used Adjusted net income (loss) (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described above) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance. It is also noted that, in recent periods, our GAAP Net income (loss) was significantly lower than our Adjusted net income (non-GAAP).

Organic Growth/Change and Organic Revenue

Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company's financial statements and might not be comparable to similar financial measures disclosed by other issuers.

Organic revenue and change in organic revenue (non-GAAP), are defined as GAAP Revenue and changes in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined further below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments and the Company in total. The Company believes that providing these non-GAAP measures is useful to investors as they provide a supplemental period-to-period comparison.

The adjustments to GAAP Revenue to determine Organic Revenue (non-GAAP) and changes in Organic Revenue (non-GAAP) are as follows:

- **Foreign currency exchange rates:** Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

- **Acquisitions, divestitures and discontinuations:** In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and change in organic revenue exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Adjusted EBITA and Adjusted EBITA Margin

Adjusted EBITA represents Operating income (loss) (its most directly comparable GAAP financial measure) adjusted to exclude amortization, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs, restructuring and integration costs, asset impairments, goodwill impairments, acquisition related costs, separation costs, separation-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP charges" above. Adjusted EBITA Margin (non-GAAP) is Adjusted EBITA (non-GAAP) divided by Revenues. The most directly comparable GAAP financial measure is operating income margin, which is Operating income (loss) divided by Revenues. On a segment basis, Adjusted EBITA represents Segment profit (its most directly comparable GAAP financial measure) adjusted to exclude the items above, as applicable.

Management believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP), along with the GAAP measures used by management, appropriately reflect how the Company measures the business internally and sets operational goals for each of its businesses. In particular, the Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) focuses management on the Company's underlying operational results and segment performance. As a result, the Company uses Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) to assess the actual financial performance of each segment and to forecast future results as part of its guidance.

The Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of the Company's profitability and the profitability of our segments as they eliminate the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted Gross Profit/Adjusted Segment Gross Profit and Adjusted Gross Margin/Adjusted Segment Gross Margin

Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) represents gross profit (its most directly comparable GAAP financial measure) adjusted for Other revenues, Cost of other revenues, Amortization of intangible assets and fair value adjustments to inventory in connection with business combinations. In accordance with GAAP, Gross profit represents total Revenues less Costs of goods sold (excluding amortization of intangible assets) less Cost of other revenues less Amortization of intangible assets. Adjusted gross margin (non-GAAP)/Adjusted segment gross margin (non-GAAP) (the most directly comparable GAAP financial measure for which is gross margin) represents Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) divided by Product revenues.

Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) are measures used by management to understand and evaluate each segment's pricing strategy, strength of product portfolio, ability to control product costs and the success of its go-to-market strategies. Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) facilitates period-to-period comparisons of each segment's ability to generate cash flows from sales, as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are non-cash charges.

The Company believes that Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitate period-to-period comparisons of each segment's ability to generate incremental cash flows from its revenues as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are non-cash charges that can be impacted by, among other things, the timing and magnitude of acquisitions, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted SG&A Expenses and Adjusted G&A Expenses

Adjusted SG&A expenses (non-GAAP) represents selling, general and administrative expenses ("SG&A expenses") (its most directly comparable GAAP financial measure) and Adjusted G&A expenses (non-GAAP) represents general and administrative expenses ("G&A expenses") (its most directly comparable GAAP financial measure), each adjusted to exclude separation-related costs and certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices and separation-related costs. See the discussion under "Other Non-GAAP charges" above.

Management uses Adjusted SG&A expenses (non-GAAP) and Adjusted G&A (non-GAAP), along with GAAP measures, as a supplemental measure for period-to-period comparison to understand and evaluate each segment's ability to control costs and direct additional cash investments in each business.

The Company believes that Adjusted SG&A (non-GAAP) and Adjusted G&A (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our SG&A expenses, G&A expenses and operations, as these measures eliminate the effects of separation-related costs and legal and other professional fees which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Total Adjusted Operating Expenses

Total Adjusted Operating Expenses (non-GAAP) represents operating expenses (its most directly comparable GAAP financial measure) adjusted to exclude restructuring and integration costs, asset impairments, including loss on assets held for sale, goodwill impairments, acquisition related costs and adjustments excluding amortization of intangible assets, separation costs, separation-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP charges" above.

Management believes that Total Adjusted Operating Expenses (non-GAAP), along with the GAAP and non-GAAP measures used by management, provide a supplemental measure for period-to-period comparison to understand and evaluate its ability manage and control its costs, assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes that Total Adjusted Operating Expenses (non-GAAP) is a useful measure to evaluate current performance amounts.

The Company believes that Total Adjusted Operating Expenses (non-GAAP) is useful to investors as it provides consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our operating expenses as Total Adjusted Operating Expenses eliminates the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances which are substantially outside of management's control.

Adjusted Cash Flows from Operations

Adjusted cash flows from operations (non-GAAP) is Cash generated from operations (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds, (ii) payments of transformation costs, (iii) payments for separation costs and separation-related costs, (iv) interest payments charged against premium, and (v) fees paid in connection with the debt exchange transaction

Management believes that Adjusted cash flows from operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses adjusted cash flows from operations (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes adjusted cash flows from operations (non-GAAP) is a useful measure to evaluate current performance amounts.

As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for the effects of changes in foreign currencies. The impact of changes in foreign currency exchange rates is determined by comparing the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Adjusted Tax Rate

Adjusted Tax Rate (the most directly comparable financial measure for which is our GAAP tax rate) includes the tax impact of the various non-GAAP adjustments used in calculating our non-GAAP measures. However, due to the differences in the tax treatment of items excluded from non-GAAP earnings, our adjusted tax rate will differ from our GAAP tax rate and from our actual tax liabilities.

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP)

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) is Adjusted EBITDA (non-GAAP) adjusted to remove Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP). Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP) is Income (loss) before income taxes of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company's interest expense, depreciation, amortization and other adjustments as described above, allocated or attributable to Bausch + Lomb.

Adjusted EBITDA excluding Bausch + Lomb is not intended to be, and may not be, representative of income from continuing operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for B+L) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to BHC excluding B+L and B+L are not in accordance with the criteria for that accounting. As such, Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Management believes that Adjusted EBITDA excluding Bausch + Lomb (non-GAAP), along with the GAAP and other non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP)

Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP) is Adjusted Cash Flow from Operations (non-GAAP) adjusted to remove Adjusted Cash Flow from Operations attributable to Bausch + Lomb (non-GAAP). Adjusted Cash Flow from Operations attributable to Bausch + Lomb (non-GAAP) is Cash Flow from Operations of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company's payment of separation costs, separation-related costs and other adjustments as described above, allocated or attributable to Bausch + Lomb.

Adjusted Cash Flow from Operations excluding Bausch + Lomb is not intended to be, and may not be, representative of Cash Flow from Operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for B+L) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to BHC excluding B+L and B+L are not in accordance with the criteria for that accounting. As such, Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the cash flows or Adjusted Cash Flow from Operations attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Management believes that Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP), along with the GAAP and other non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our cash flows and therefore reflects our financial performance based on operational factors.